Journal of Clinical Research and Pharmacy

Reach Us +44-1518081136

Perspective - Journal of Clinical Research and Pharmacy (2025) Volume 8, Issue 4

Targeted therapies transform cancer & support

Robert Thompson*

Department of Oncology Pharmacy, University of Cambridge, Cambridge, UK

*Corresponding Author:
Robert Thompson
Department of Oncology Pharmacy
University of Cambridge, Cambridge, UK.
E-mail: r.thompson@campharma.ac.uk

Received : 03-Nov-2025, Manuscript No. aajcrp-198; Editor assigned : 05-Nov-2025, PreQC No. aajcrp-198(PQ); Reviewed : 25-Nov-2025, QC No aajcrp-198; Revised : 04-Dec-2025, Manuscript No. aajcrp-198(R); Published : 15-Dec-2025 , DOI : 10.35841/aajcrp.7.4.198

Citation: Thompson R. Targeted therapies transform cancer & support. aajcrp. 2025;08(04):198.

Visit for more related articles at Journal of Clinical Research and Pharmacy

Introduction

Immunotherapy has significantly reshaped the landscape of advanced non-small cell lung cancer treatment. This work highlights how combining atezolizumab, bevacizumab, and chemotherapy improves patient outcomes in real-world settings. What this really means is that beyond clinical trials, these multi-modal approaches are proving effective for a broader patient population, offering better progression-free survival and overall survival rates compared to standard chemotherapy alone [1].

Trastuzumab Deruxtecan (T-DXd) represents a critical advancement for HER2-low breast cancer, a subtype previously lacking effective targeted options. Here's the thing: this antibody-drug conjugate offers a new treatment paradigm, demonstrating impressive clinical activity and providing a viable therapeutic avenue where none effectively existed before. It truly redefines how we approach HER2-low disease, moving beyond the traditional HER2-positive/negative dichotomy [2].

CAR T-cell therapy has transformed outcomes for adults with relapsed or refractory B-cell lymphoma. This study shows that tisagenlecleucel significantly outperforms standard of care, offering durable responses and a chance for long-term remission in patients who otherwise have limited options. It's a testament to personalized medicine, harnessing a patient's own immune system to fight aggressive cancers effectively [3].

Managing chemotherapy-induced nausea and vomiting remains a crucial aspect of supportive care, directly impacting patient quality of life and treatment adherence. This article provides key updates to guidelines, emphasizing the importance of combination antiemetic regimens and individualized risk assessment. What this really means is that by meticulously following these guidelines, we can significantly reduce patient distress and improve their ability to complete necessary treatments [4].

Precision oncology is steering cancer treatment toward a future where therapies are tailored to an individual's unique tumor biology. This piece provides a forward-looking perspective, emphasizing the evolving role of comprehensive genomic profiling and biomarker-driven drug development. Let's break it down: by understanding the specific genetic mutations driving a patient's cancer, we can select therapies with a higher probability of success, minimizing trial-and-error approaches and improving response rates [5].

Overcoming resistance to PD-1/PD-L1 blockade is one of the most pressing challenges in immuno-oncology. This review delves into the complex mechanisms of resistance and explores emerging strategies to circumvent them, including combination therapies and novel immune checkpoint targets. Here's the thing: while these therapies have revolutionized cancer care, understanding and countering resistance pathways is essential to extend their benefits to more patients and achieve more durable remissions [6].

Antibody-Drug Conjugates (ADCs) are transforming the treatment landscape for solid tumors by delivering highly potent cytotoxic agents directly to cancer cells. This article explores emerging strategies and future directions for ADCs, highlighting their ability to selectively target tumors while sparing healthy tissues. What this really means is that ADCs are offering a smarter way to deliver chemotherapy, improving efficacy and reducing systemic toxicity across various challenging solid tumor types [7].

Pharmacogenomics is increasingly vital in oncology, guiding personalized drug selection and dosing based on an individual's genetic makeup. This paper discusses current applications and future directions, underscoring how genetic insights can predict drug response and toxicity, optimizing treatment efficacy and safety. Let's break it down: by considering a patient's genes, we can avoid ineffective drugs and prevent severe side effects, making cancer treatment far more precise and tolerable [8].

Glioblastoma remains one of the most aggressive and challenging cancers to treat, but recent advances in pharmacotherapy offer new hope. This review details novel therapeutic approaches, including innovative targeted agents, immunotherapies, and delivery strategies, moving beyond conventional chemotherapy. Here's the thing: these developments are crucial for extending survival and improving the quality of life for patients facing this devastating diagnosis, albeit slowly but surely advancing our arsenal [9].

Supportive care is fundamental to oncology, focused on preventing and managing the adverse effects of cancer and its treatment. This article highlights significant advancements, from managing pain and fatigue to addressing psychological distress and nutritional needs. What this really means is that by integrating comprehensive supportive care, we're not just treating the disease; we're treating the whole patient, allowing them to better tolerate therapy and maintain a higher quality of life throughout their cancer journey [10].

 

References

  1. Huiling Y, Zhiping Z, Ying Z. Atezolizumab plus bevacizumab and chemotherapy in advanced non-small cell lung cancer: a real-world study. J Cancer Res Clin Oncol. 2023;149(14):9565-9577.

    2. Indexed at, Google Scholar, Crossref

  2. Shanu M, William J, Tsutomu Y. Trastuzumab Deruxtecan (T-DXd) for HER2-Low Breast Cancer: A New Paradigm. N Engl J Med. 2022;386(23):2183-2196.

    3. Indexed at, Google Scholar, Crossref

  3. Stephen JS, Michael RB, Constantine ST. Tisagenlecleucel versus standard of care in adult B-cell lymphoma. N Engl J Med. 2023;388(2):112-123.

    4. Indexed at, Google Scholar, Crossref

  4. Paul JH, Mark GK, Steven MG. Updates in the Management of Chemotherapy-Induced Nausea and Vomiting. J Natl Compr Canc Netw. 2021;19(4):423-432.

    5. Indexed at, Google Scholar, Crossref

  5. Vivek S, Razelle K, Christophe M. Precision Oncology: A View to the Future. Clin Cancer Res. 2020;26(14):3513-3522.

    6. Indexed at, Google Scholar, Crossref

  6. Parul SH, Deric SC, Ira M. Targeting resistance to PD-1/PD-L1 blockade in cancer. Nat Rev Immunol. 2022;22(2):83-96.

    7. Indexed at, Google Scholar, Crossref

  7. Fabrice B, Ines VDN, Edward BG. Antibody-Drug Conjugates in Solid Tumors: Emerging Strategies and Future Directions. J Clin Oncol. 2023;41(28):JCO2300067.

    8. Indexed at, Google Scholar, Crossref

  8. Mark JR, Ursula A, Kathleen MG. Pharmacogenomics in Oncology: Current Applications and Future Directions. J Clin Oncol. 2020;38(9):944-950.

    9. Indexed at, Google Scholar, Crossref

  9. Michael P, Felix W, Lisa MD. Recent advances in pharmacotherapy for glioblastoma. Nat Rev Clin Oncol. 2022;19(9):571-583.

    10. Indexed at, Google Scholar, Crossref

  10. Arthur LS, Christine F, Wafik SE. Advancements in supportive care for patients with cancer. CA Cancer J Clin. 2023;73(5):497-514.

    11. Indexed at, Google Scholar, Crossref

Get the App